PGEN News and Press, Precigen Inc.

2024-06-03 14:30:04 ET Stifel Nicolaus analyst issues MARKET OUTPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Market Outperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst co...

2024-06-03 14:30:03 ET JMP Securities analyst issues UNDERPERFORM recommendation for PGEN on June 3, 2024 01:00PM ET. The previous analyst recommendation was Underperform. PGEN was trading at $1.53 at issue of the analyst recommendation. The overall analyst consensus : B...

2024-06-03 11:15:32 ET More on Precigen Investors Prep For A Key Jobs Report Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript Precigen Q1 2024 Earnings Preview J.P. Morgan cuts Precigen to underweight, cites burn rate Seeking Alpha’s Quan...

Precigen Announces Groundbreaking Pivotal Study Data for PRGN-2012 in Patients with Recurrent Respiratory Papillomatosis in Which More than Half of Patients Achieved Complete Response PR Newswire – Phase 1/2 pivotal study met the primary safety and efficacy endpoints &#...

2024-06-01 10:00:00 ET Get ahead of the market by subscribing to Seeking Alpha's Stocks to Watch, a preview of key events scheduled for the coming week. The newsletter keeps you informed of the biggest stories set to make headlines, including upcoming IPOs, investor days, earnings reports a...

2024-05-31 15:00:19 ET More on the markets Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity S&P 500: It Is All About Liquidity SPY: Time To Be Contrarian And Underweight Hedge funds back at record exposure to Magnificent 7 S&am...

Precigen to Host a Webcast on June 3rd to Detail Pivotal Study Results of PRGN-2012 in Recurrent Respiratory Papillomatosis Presented at the 2024 ASCO Annual Meeting PR Newswire GERMANTOWN, Md. , May 23, 2024 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a b...

2024-05-14 16:06:44 ET More on Precigen Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript Precigen Q1 2024 Earnings Preview J.P. Morgan cuts Precigen to underweight, cites burn rate Seeking Alpha’s Quant Rating on Precigen Historical earni...

Precigen Reports First Quarter 2024 Financial Results and Business Updates PR Newswire – Pivotal Phase 2 study data of PRGN-2012 for the treatment of patients with recurrent respiratory papillomatosis to be presented at the 2024 ASCO Annual Meeting as a late-breaking or...

2024-05-13 12:16:06 ET More on Precigen Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript J.P. Morgan cuts Precigen to underweight, cites burn rate Seeking Alpha’s Quant Rating on Precigen Historical earnings data for Precigen Financial in...